Search Results

Your search for Leo I. Gordon, MD, FACP matches 2 pages

Showing 1 - 2

By Leo I. Gordon, MD, FACP / November 10, 2022

‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs

As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...

leukemia

By Leo I. Gordon, MD, FACP / July 10, 2017

Idelalisib in Resistant CLL: Benefit Shown, Questions Remain

As reported in The Lancet Oncology by Dr. Andrew Zelenetz and colleagues and reviewed in this issue of The ASCO Post, an international phase III trial in 416 patients with refractory or recurrent chronic lymphocytic leukemia (CLL) addressed the benefit of adding the first-in-class phosphoinositide...

Feb

Today In Oncology

Search Results

Your search for Leo I. Gordon, MD, FACP matches 2 pages

‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs

Idelalisib in Resistant CLL: Benefit Shown, Questions Remain

Preclinical Study Shows Losartan May Prevent Immune Checkpoint Inhibitor Induced Cerebral Edema in Glioblastoma

Researchers Uncover Racial and Ethnic Disparities in Widely Used Precision Oncology Data Registry

Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer and High FRa Expression

ctDNA as a Prognostic Marker in Intermediate-Risk Rhabdomyosarcoma

Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer in Survivors of Hodgkin Lymphoma